Sirolimus
- Generic Name
- Sirolimus
- Brand Names
- Fyarro, Hyftor, Rapamune
- Drug Type
- Small Molecule
- Chemical Formula
- C51H79NO13
- CAS Number
- 53123-88-9
- Unique Ingredient Identifier
- W36ZG6FT64
- Background
Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria Streptomyces hygroscopicus, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive a...
- Indication
Sirolimus is indicated for the prophylaxis of organ rejection in patients aged 13 years or older receiving renal transplants. In patients at low-to moderate-immunologic risk, it is recommended that sirolimus be used initially in a regimen with cyclosporine and corticosteroids; cyclosporine should be withdrawn two to four months after transplantation. In pati...
- Associated Conditions
- Chordomas, Facial Angiofibroma, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Liver Transplant Rejection, Lung Transplant Rejection, Lymphangioleiomyomatosis (LAM), Renal Angiomyolipomas, Transplanted Organ Rejection, Metastatic malignant Perivascular Epithelioid Cell Neoplasms, Unresectable, locally advanced malignant Perivascular Epithelioid Cell Neoplasms
- Associated Therapies
- -
Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex
- Conditions
- Interventions
- First Posted Date
- 2019-02-01
- Last Posted Date
- 2023-09-08
- Lead Sponsor
- Dermatology Specialties Limited Partnership
- Target Recruit Count
- 107
- Registration Number
- NCT03826628
- Locations
- 🇭🇺
University of Pécs, Pécs, Hungary
🇺🇸University of California San Diego, La Jolla, California, United States
🇪🇸Clinica Universidad de Navarra, Pamplona, Navarra, Spain
Efficacy of Rapamycin (Sirolimus) in the Treatment of Peutz-Jeghers Syndrome
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2019-01-23
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT03781050
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Chinese Academy of Medicine Sciences, Beijing, China/Beijing, China
Efficacy of Rapamycin (Sirolimus) in the Treatment of BRBNS, Hereditary or Sporadic Venous Malformation
- First Posted Date
- 2018-12-06
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT03767660
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Chinese Academy of Medicine Sciences, Beijing, Beijing, China
Bioequivalence Study of NPC-12 (Sirolimus) Granules and Tablets
- First Posted Date
- 2018-12-05
- Last Posted Date
- 2019-02-25
- Lead Sponsor
- Nobelpharma
- Target Recruit Count
- 10
- Registration Number
- NCT03765944
- Locations
- 🇯🇵
Clinique Soigner, Matsudo, Chiba, Japan
Altering Memories That Increase Risk of Relapse in Alcohol Use Disorders
- Conditions
- Interventions
- First Posted Date
- 2018-11-06
- Last Posted Date
- 2021-01-27
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 21
- Registration Number
- NCT03732248
- Locations
- 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
Study of Sirolimus in CTD-TP in China
- First Posted Date
- 2018-09-28
- Last Posted Date
- 2019-04-17
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT03688191
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Study of Sirolimus in Patients With Advanced Pancreatic Cancer
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2018-09-07
- Target Recruit Count
- 36
- Registration Number
- NCT03662412
- Locations
- 🇨🇳
The second affiliated hospital of Zhejiang University, Hangzhou, Zhejiang, China
CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease
- Conditions
- Interventions
- First Posted Date
- 2018-07-30
- Last Posted Date
- 2024-11-27
- Target Recruit Count
- 45
- Registration Number
- NCT03605927
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸City of Hope Cancer Center, Duarte, California, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Efficacy and Safety of Sirolimus to Vascular Anomalies
- First Posted Date
- 2018-07-11
- Last Posted Date
- 2022-03-15
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 126
- Registration Number
- NCT03583307
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China
Human Lysozyme Goat Milk in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2018-05-21
- Last Posted Date
- 2018-12-07
- Lead Sponsor
- City of Hope Medical Center
- Registration Number
- NCT03531281
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.